Valneva's first-half product sales fell from €91 million to €64 million, but it kept its 2026 sales forecast and reported cash above €120 million. Its Lyme vaccine results showed promise but missed the lower confidence limit, leaving the overall outlook mixed.
The Lyme vaccine could become important, but its study missed the lower limit of its 95% confidence range. Its reported result above 70% and a second analysis above 20% offer promise, but a decision is still ahead. Cost cuts may help later this year, but their benefits have not yet appeared.
Follow Valneva (VALN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VALN